Let us start with what you were probably told.

Hot flashes. Night sweats. Periods becoming irregular. The end of fertility. A vague suggestion that mood might be affected. Perhaps a mention of vaginal dryness, delivered quickly and quietly, as though it were an embarrassing footnote rather than a significant health matter affecting the quality of daily life.

That is the version of perimenopause that makes it into the conversation. It is incomplete to the point of being misleading. And the gap between what women are told and what they actually experience has been quietly costing them, in misdiagnoses, unnecessary suffering, and the corrosive belief that the things happening to their bodies are somehow their own fault.

At Birch & Wilde, we are done with the incomplete version. This is the honest one.

What perimenopause actually is, and when it starts

Perimenopause is the transitional phase preceding menopause, during which the ovaries gradually reduce their production of oestrogen, progesterone, and testosterone. It is not a single event. It is a process that can last anywhere from two to twelve years, typically beginning in a woman’s early to mid-forties, though it can start considerably earlier.

The defining hormonal feature is not simply that oestrogen declines. It is that it declines erratically, fluctuating unpredictably before settling into a sustained downward trajectory. This irregularity is precisely why perimenopause produces such a varied and often bewildering range of symptoms. The body is not responding to a steady new hormonal state. It is responding to a constantly shifting one.

Eighty to ninety percent of women experience symptoms during the perimenopause transition. That is not a minority experience. That is the near-universal reality of being a woman in midlife, and it deserves to be discussed with the same seriousness and the same research investment as any other health matter affecting this proportion of the population.

The brain. What is actually happening.

Approximately two thirds of perimenopausal women report significant cognitive changes, what many describe as brain fog, a cotton wool quality to thought that makes the mind feel slower, less reliable, and genuinely frightening to those who have built their lives around mental sharpness.

The mechanism is direct and well documented. Oestrogen receptors are densely concentrated in the hippocampus and prefrontal cortex, the brain regions responsible for memory formation, verbal fluency, attention, and executive function. Oestrogen stimulates neurons, supports the growth of new brain cells, helps existing cells form new connections, and drives the brain’s glucose metabolism, its primary fuel source.

When oestrogen levels begin to decline, the brain enters what researchers describe as a deprivation state. Studies published in 2025 have documented measurable reductions in grey matter volume in the frontal and temporal cortices during the menopausal transition, with corresponding declines in verbal and working memory performance.

Testosterone, which also declines significantly during perimenopause, compounds this picture. A 2025 study of 510 perimenopausal and postmenopausal women found that 92 percent reported fatigue or lack of energy, and 59 percent reported attacks of anxiety or panic. Testosterone deficiency is now understood to contribute directly to brain fog, depressed mood, and cognitive fatigue in midlife women, yet it remains almost entirely absent from the standard clinical conversation about menopause.

The good news, and this is worth holding: the most significant cognitive symptoms tend to cluster during the transition itself. Research consistently shows that many women experience a meaningful improvement in cognitive clarity once they reach postmenopause and hormone levels stabilise at their new baseline. You are not losing your mind. You are moving through a transition that your brain will adapt to.

The joints. What nobody connects.

A meta-analysis of over 93,000 women confirmed what enormous numbers of women have known from experience and been unable to get anyone to take seriously: joint pain, muscle aches, and musculoskeletal symptoms are a real, prevalent, and hormonally driven feature of perimenopause, not simply a consequence of ageing.

Oestrogen plays a direct role in maintaining cartilage integrity, joint lubrication, and inflammation regulation throughout the body. When oestrogen declines, joints lose some of that protection. Ligaments show altered laxity and reduced tensile strength. The result is pain, stiffness, cracking, and a vulnerability to injury that many women attribute to getting older rather than to a specific and identifiable hormonal cause.

Declining oestrogen is also associated with musculoskeletal symptoms in around 70 percent of peri and postmenopausal women. Declining testosterone compounds this further by reducing muscle mass and bone density. The woman in her mid-forties who suddenly finds that her knees ache, her shoulders are stiff, or her heels hurt when she gets out of bed in the morning is not imagining it, and she is not simply ageing badly. She is experiencing a documented, hormonally driven syndrome that has a name, a mechanism, and treatments.

The weight. What oestrogen does when it leaves.

Weight redistribution during perimenopause is one of the most universally experienced and least adequately explained phenomena in women’s health. Women who have maintained a stable weight for decades find that fat accumulates around the abdomen despite no change in diet or exercise. The waist thickens. The strategies that always worked stop working. The body appears to be operating by a different set of rules.

It is. As oestrogen produced by the ovaries begins to decline, the body attempts to compensate by drawing oestrogen from an alternative source: fat cells, which produce a weaker form of oestrogen. The body, in a form of biological pragmatism, begins to store more abdominal fat as a way of maintaining some oestrogen supply. This process is further driven by rising cortisol, the stress hormone that surges as the hormonal balance shifts, which signals the body to release glucose and, when that energy is not burned, to store it as fat.

The result is a body that is responding intelligently, if frustratingly, to a changed hormonal environment. Understanding the mechanism does not make it less annoying. But it does remove the entirely false suggestion that the woman is at fault.

The cortisol cascade. The connection everyone misses.

This is the piece of the perimenopause picture that is most consistently absent from the clinical conversation and most consequential for understanding why the whole experience feels so destabilising.

Oestrogen and progesterone both play a direct regulatory role in the body’s stress response system. Progesterone, in particular, has a calming, anti-anxiety effect on the nervous system, binding to the same receptors as some anti-anxiety medications. When progesterone declines, that natural buffer is removed. The nervous system becomes more reactive. Cortisol, the primary stress hormone, is less effectively regulated and tends to run higher.

Elevated cortisol then drives a cascade of effects that compound every other perimenopausal symptom: disrupted sleep, increased abdominal fat storage, impaired memory and concentration, heightened anxiety, and increased inflammation throughout the body, including in the joints. The woman who finds that her anxiety has increased, her sleep has deteriorated, her weight has shifted, and her joints ache is not experiencing four separate problems. She is experiencing one interconnected cascade, and cortisol is running through the centre of it.

High cortisol levels from the hormonal disruption of perimenopause are now understood to directly affect the hippocampus, the brain region most critical for memory, which means the cortisol cascade and the cognitive changes are not separate symptoms either. They are the same symptom expressed through different systems.

The genitourinary changes. The symptoms women piece together alone.

Genitourinary Syndrome of Menopause, known as GSM, is a chronic and progressive condition caused by oestrogen deficiency in the urogenital tissue, affecting the vulva, vagina, urethra, and bladder. It affects between 36 and 90 percent of perimenopausal and postmenopausal women. It is undertreated, underdiagnosed, and almost never discussed proactively in clinical consultations.

When oestrogen declines, the tissues of the vagina and urethra thin, lose elasticity, become drier and more fragile, and the local pH changes in ways that alter the microbiome and increase vulnerability to irritation, infection, and pain. The labia thin. Hyaluronic acid synthesis in the vaginal tissue decreases. Collagen and elastic fibres reduce. The vagina can become shorter and narrower, causing pain during intercourse. The bladder and urethra atrophy, leading to increased urinary frequency, urgency, and recurrent urinary tract infections.

That last point deserves particular attention. Many perimenopausal women experience what appears to be a UTI, test positive for elevated white blood cells in their urine, are prescribed antibiotics, and find that the antibiotics do nothing. This is because the elevated white blood cells can be a consequence of inflamed, atrophied urogenital tissue rather than bacterial infection. Repeated unnecessary antibiotic courses then disrupt the vaginal microbiome, which worsens the GSM, which produces more symptoms, which produces more misdiagnoses. It is a cycle that could be interrupted at the first consultation if the clinician understood what they were looking at.

The women who figure this out do so through each other. Through forums, comment sections, and the kind of frank, detailed, unglamorous conversations that the medical system has historically been too uncomfortable to have. They share what works. Vaginal oestrogen. Hyaluronic acid inserts for hydration. Vaginal probiotics to support the microbiome. Boric acid inserts for pH balance. D-Mannose for urinary tract support. Careful post-sex hygiene.

None of these women should have had to piece this together alone. The information exists. It has simply not been delivered to them in a clinical setting with the consistency and directness it deserves.

What B&W wants to say plainly

We sell supplements. We are not going to pretend that any capsule resolves the hormonal reality of perimenopause, because it does not. What we can honestly offer is support for some of the physiological demands that the transition places on the body.

Ashwagandha has one of the most robust evidence bases of any adaptogen for its ability to regulate cortisol and support the nervous system under sustained pressure. For the perimenopausal woman whose cortisol is running high and whose stress response has lost some of its natural progesterone buffer, this is a relevant and evidence-informed form of support.

The Vitamin B Complex supports nervous system function, energy metabolism, mood regulation, and the production of serotonin and dopamine, all of which are directly affected by the hormonal shifts of perimenopause. B vitamins are among the first nutritional casualties of chronic stress and sleep deprivation, both of which the perimenopausal transition reliably produces.

Marine Collagen supports the structural integrity of connective tissue, skin, and joints, all of which are affected by declining oestrogen. Consistent supplementation over time supports what oestrogen withdrawal quietly erodes.

And D-Mannose, while not a treatment for GSM or for hormonally driven urinary changes, supports urinary tract health in a way that is relevant for women navigating the increased vulnerability that perimenopause brings.

None of these are solutions to perimenopause. They are support for a body doing something genuinely demanding, at a stage of life that deserves more than hot flash mentions and a shrug.

The most important thing

If you recognise yourself in any part of this piece, please take what you have read to a doctor, ideally one with a specific interest in menopause and women’s hormonal health. The British Menopause Society maintains a directory of accredited menopause specialists at thebms.org.uk. You do not have to accept a consultation that dismisses your symptoms as stress or ageing. You deserve a clinician who understands what is actually happening in your body.

And if you are the woman who has been quietly piecing this together from forum comments and other women’s experiences, because the clinical system has not provided what you needed: we see you. What you are living through is real, documented, and not your fault.

Sources

The Menopause Charity. Brain Fog. themenopausecharity.org

Menopause Science. Menopause Brain Fog: 2026 Research and Management Tips. menopause.science, April 2026.

North American Menopause Society. How Menopause Restructures a Woman’s Brain. menopause.org, October 2025.

PHYT Collective. Perimenopause Joint Pain: What the Research Actually Shows. phytcollective.com, 2026.

Journal of Sexual Medicine. Effect of Testosterone Therapy on Musculoskeletal Pain in Perimenopausal and Postmenopausal Women. academic.oup.com, April 2025.

The Menopause Charity. Weight Change. themenopausecharity.org

British Menopause Society. Consensus Statement: Genitourinary Syndrome of Menopause. thebms.org.uk, November 2025.

Simon, J.A. et al. Genitourinary Syndrome of Menopause: Recommendations from the Fifth International Consultation on Sexual Medicine. Sexual Medicine Reviews, 2025. academic.oup.com

NHS Sherwood Forest Hospitals. Menopause and Musculoskeletal Health: Patient Information. sfh-tr.nhs.uk, 2025.